PRESS RELEASE
Wednesday, 05 February 2014

Zosano Pharma Enters into a License Agreement with Novo Nordisk to Deliver Semaglutide Using Zosano’s Microneedle Patch System

Fremont, California, February 5, 2014 /PRNewswire/ — Zosano Pharma, Inc., (Zosano) announced today that it has entered into an agreement with Novo Nordisk A/S (NVO) to develop a new transdermal presentation of semaglutide, an investigational proprietary human GLP-1 (Glucagon-Like Peptide-1) analogue, to be administered once weekly using Zosano’s microneedle patch system for the treatment of type 2 diabetes.

Read more...
 
Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer
Tuesday, 14 May 2013

Fremont, CA — May 14, 2013 — Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with the appointment of Nandan Oza as the company's Chief Operations Officer. In this position, Mr. Oza will guide the company’s efforts in manufacturing, quality and engineering — vital activities to enable the company to accelerate the development of its innovative multi-product portfolio.

Read more...
 
Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
Monday, 15 April 2013

Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.

Fremont, CA — April 15, 2013 — Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today the appointment of Kleanthis G. Xanthopoulos, Ph.D., to its Board of Directors. Dr. Xanthopoulos is President & Chief Executive Officer of Regulus Therapeutics Inc.(NASDAQ:RGLS), a leading company developing microRNA therapeutics.

Read more...
 
Zosano Pharma, Inc. Announces Key Strategic Hire
Tuesday, 09 April 2013

Seasoned Business Development Executive Chris Krueger Joins as Chief Business Officer

Fremont, CA — April 9, 2013 — Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today that Chris Krueger has been appointed as the company's Chief Business Officer. In this position, Mr. Krueger will be responsible for the company's business development, legal, and investor relations activities.

Read more...
 
Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement
Tuesday, 11 October 2011

Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis

Asahi Kasei Pharma Obtains Exclusive Rights in Osteoporosis in Japan, China, Korea and Taiwan (Asia)

FREMONT, Calif. and TOKYO, Oct. 10, 2011 /PRNewswire/ — Zosano Pharma, Inc. (Zosano) and Asahi Kasei Pharma Corporation (AKP) announced today that they have entered into a long–term strategic collaboration for the development, commercialization and supply of a weekly transdermal patch formulation of Teribone™ (teriparatide acetate), AKP's formulation of human parathyroid hormone (human PTH 1–34), for the treatment of osteoporosis patients with a high risk of fracture.

Read more...
 
Contact   |   Sitemap   |   Legal
  |   Design: Formative